Featured
-
-
Article
| Open Access
Nanoparticle-based DNA vaccine protects against SARS-CoV-2 variants in female preclinical models
Here the authors screen different lipid nanoparticle (LNP) formulations for intramuscular delivery of plasmid DNA and uptake by antigen-presenting cells. The lead LNP exhibits immunogenicity and protection in small animal models that is comparable to approved SARS-CoV-2 mRNA vaccine formulations.
- Lays Cordeiro Guimaraes
- , Pedro Augusto Carvalho Costa
- & Pedro Pires Goulart Guimaraes
-
Article
| Open Access
ChAd155-RSV vaccine is immunogenic and efficacious against bovine RSV infection-induced disease in young calves
A pediatric RSV vaccine is an unmet medical need, even after >50 years of effort. Here, the authors show that a chimpanzee adenovirus based RSV vaccine candidate protects calves from disease upon RSV infection, regardless of the time after vaccination (1 or 4 months) or the presence of maternal antibodies.
- Rineke de Jong
- , Norbert Stockhofe-Zurwieden
- & Ann-Muriel Steff
-
Article
| Open Access
Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines
Here the authors show that an HIV vaccine in non-human primates that focuses antibodies on the V1V2 region of gp120 is superior to infection or immunization with whole envelope vaccines for inducing V1V2 antibodies with anti-viral functions that correlate with protection.
- Svenja Weiss
- , Vincenza Itri
- & Susan Zolla-Pazner
-
Article
| Open Access
Induction of tier-2 neutralizing antibodies in mice with a DNA-encoded HIV envelope native like trimer
HIV envelope is a target for vaccine development, but induction of broadly neutralizing antibodies has been difficult. Here, the authors show that electroporation with a synthetic DNA vaccine construct allows in vivo production of HIV envelope native like trimers to induce autologous tier-2 neutralizing antibodies targeting a C3/V5 epitope in mice.
- Ziyang Xu
- , Susanne Walker
- & Daniel W. Kulp
-
Article
| Open Access
Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization
While current COVID-19 vaccines provide certain protection, more effective vaccination strategies are still desirable. Here the authors show, using mouse vaccination models, that priming with a systemic mRNA and boosting with an intranasal adenoviral vector vaccine induces comprehensive T cell and mucosal immunity.
- Dennis Lapuente
- , Jana Fuchs
- & Matthias Tenbusch
-
Article
| Open Access
Malignant cerebral infarction after ChAdOx1 nCov-19 vaccination: a catastrophic variant of vaccine-induced immune thrombotic thrombocytopenia
Vaccination is an effective strategy in suppressing COVID-19 pandemic, but rare adverse effects have been reported, including cerebral venous thrombosis. Here the authors report two cases of middle cerebral artery infarct within 9-10 days following ChAdOx1 nCov-19 vaccination that also manifest pulmonary and portal vein thrombosis.
- M. De Michele
- , M. Iacobucci
- & D. Toni
-
Article
| Open Access
Immunogenicity of a DNA vaccine candidate for COVID-19
There is currently no licensed SARS-CoV-2 vaccine. Here, the authors generate an optimized DNA vaccine candidate encoding the SARS-CoV-2 spike antigen, demonstrating induction of specific T cells and neutralizing antibody responses in mice and guinea pigs. These initial results support further development of this vaccine candidate.
- Trevor R. F. Smith
- , Ami Patel
- & Kate E. Broderick
-
Article
| Open Access
Development of a SFTSV DNA vaccine that confers complete protection against lethal infection in ferrets
Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging tick-borne virus with no specific treatment or vaccine available. Here, the authors develop a DNA vaccine for SFTSV that is protective against lethal challenge in ferrets and show that anti-envelope antibodies are important for protection.
- Jeong-Eun Kwak
- , Young-Il Kim
- & Su-Hyung Park
-
Article
| Open Access
Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions
Adenovirus based (AdV) vectors are promising platforms for therapeutics and vaccines, but receptor usage of serotypes in clinical development remains unclear. Here, based on crystal structures and modeling, Baker et al. show that HAdV-D26/48 fiber knob protein interacts weakly with CAR but not with CD46 or DSG2.
- Alexander T. Baker
- , Alexander Greenshields-Watson
- & Alan L. Parker
-
Article
| Open Access
DNA vaccination protects mice against Zika virus-induced damage to the testes
Zika virus (ZIKV) can persist in human semen and sperm, which can result in sexual transmission. Here, Griffinet al. show that a DNA vaccine, expressing ZIKV pre-membrane and envelope proteins, protects mice from infection-associated damage to testes and sperm, and prevents viral persistence in testes.
- Bryan D. Griffin
- , Kar Muthumani
- & Gary P. Kobinger
-
Article
| Open Access
Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients
While several human papilloma virus (HPV) vaccines exist, a highly effective vaccine that mediates regression of HPV-induced tumours is lacking. Here the authors show that a therapeutic DNA vaccine-induced HPV-specific polyfunctional CD8 T cell in 7 out of 9 patients who all exhibited complete regression of lesions and viral clearance.
- Tae Jin Kim
- , Hyun-Tak Jin
- & Young Chul Sung
Applying valency-based immuno-selection to generate broadly cross-reactive antibodies against influenza hemagglutinins